The capture of the US healthcare system has created a devastating reality: insurance giants, pharmaceutical benefit managers (PBMs), and a "wack-a-mole" symptom-management model consistently prioritize short-term quarterly profits over long-term human wellness.
But there is a hidden casualty downstream of this broken system that rarely makes the headlines: innovation within orthopedics.
If you are an early-stage company developing a breakthrough orthopedic device—whether it’s an advanced joint replacement implant, a minimally invasive spinal stabilization tool, or a novel biologic designed to regenerate cartilage—the current insurance landscape isn’t just a hurdle. It is a brick wall.
Here is exactly how structural flaws in the reimbursement matrix are choking out orthopedic startups and leaving patients trapped in a cycle of chronic pain.
The Death of Preventive Orthopedics and the "Two-Year" Trap
A cynical reality of the insurance industry is the financial incentive to delay care. Because the average American switches employers (and therefore insurance plans) roughly every two years, insurance companies have zero financial motive to cover early, preventive treatments. Why pay fo...
